Accedi a banche dati online | Convegnodetail
mail
Anteprima di stampa
 
 

2nd ALS Drug Development Summit

Evvnt Promotion / evvnt
-
16.05.2023 - 18.05.2023  Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
9:00 am - 4:30 pm
 
Temi della conferenza
Following the approval of Amylyx's Relyvrio in the US and Canada and further FDA decisions on the horizon in 2023, the ALS drug development landscape is gaining momentum and positivity. With booming pharma investment and new biotechs entering the field, there are still crucial translational challenges to address to bridge the gap and see clinical success for the wider ALS patient population.
Professional congress organizer (PCO)
Hanson Wade
Annotazioni
URL:
Brochure: https://go.evvnt.com/1485150-3?pid=4832

Speakers: Alain Moussy, Co-Founder and Chief Executive Officer, AB Science, and more.
 

Informazioni ed Iscrizioni:

https://go.evvnt.com/1485150-2?pid=4832
Ms. Erin Thomas
 
Categorie
Medicina General
Lingua
Inglese
Quote del Congresso
USD 2599.00 - USD 5297.00
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."

European Health Forum GasteinnewTreeCenter of ExcellenceAGEM - Arbeitsgemeinschaft Ethnologie und MedizinÄrzte der WeltÄrztekammer für WienAlumni Club Medizinische Universität WienCharité International Academy